The Hepatitis E drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatitis E, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatitis E. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatitis E and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Hepatitis E by seven companies/universities/institutes. The top development phase for Hepatitis E is preclinical with two drugs in that stage. The Hepatitis E pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Hepatitis E pipeline products market are: University of Lubeck, Chongqing Zhifei Biological Products and Zydus Lifesciences.
The key targets in the Hepatitis E pipeline products market include Capsid Protein.
The key mechanisms of action in the Hepatitis E pipeline product include Capsid Protein Inhibitor with one drug in Preclinical. The Hepatitis E pipeline products include one routes of administration with the top ROA being Intramuscular and four key molecule types in the Hepatitis E pipeline products market including Vaccine, and Subunit Vaccine.
Hepatitis E overview
Hepatitis E is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. It is caused by the hepatitis E virus (HEV). The virus has at least 4 different types: genotypes 1, 2, 3 and 4. Genotypes 1 and 2 have been found only in humans. Genotypes 3 and 4 circulate in several animals including pigs, wild boars and deer without causing any disease, and occasionally infect humans.
For a complete picture of Hepatitis E’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
